Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	105	39.21	47.07	78.59	46.83	72.83
Revenue Growth	134.84%	-16.70%	-40.11%	67.84%	-35.71%	114.00%
Cost of Revenue	375.57	316.57	240.25	189.08	164.25	137.02
Gross Profit	-270.57	-277.36	-193.18	-110.49	-117.42	-64.19
Selling, General & Admin	75.76	68.19	63.53	55.04	43.83	36.35
Operating Expenses	75.76	68.19	63.53	55.04	43.83	36.35
Operating Income	-346.32	-345.54	-256.71	-165.53	-161.26	-100.53
Interest Expense	-0.34	-0.37	-0.25	-0.2	-0.18	-0.18
Interest & Investment Income	50.91	38.42	38.03	18.76	6.62	0.49
EBT Excluding Unusual Items	-295.75	-307.5	-218.93	-146.96	-154.81	-100.22
Asset Writedown	-3.86	-3.86	-4.93	-	-	-
Pretax Income	-299.6	-311.35	-223.86	-146.96	-154.81	-100.22
Net Income	-299.6	-311.35	-223.86	-146.96	-154.81	-100.22
Net Income to Common	-299.6	-311.35	-223.86	-146.96	-154.81	-100.22
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	93	84	75	58	54	48
Shares Outstanding (Diluted)	93	84	75	58	54	48
Shares Change	17.71%	12.59%	28.58%	8.22%	12.39%	176.60%
EPS (Basic)	-3.21	-3.69	-2.98	-2.52	-2.87	-2.09
EPS (Diluted)	-3.21	-3.69	-2.98	-2.52	-2.87	-2.09
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-237.96	-234.34	-207.34	-137.31	-155.92	-130.54
Free Cash Flow Per Share	-2.55	-2.77	-2.76	-2.35	-2.89	-2.72
Gross Margin	-257.69%	-	-	-140.59%	-250.76%	-88.13%
Operating Margin	-329.83%	-881.24%	-545.36%	-210.62%	-344.37%	-138.03%
Profit Margin	-285.33%	-794.04%	-475.56%	-186.99%	-330.60%	-137.60%
Free Cash Flow Margin	-226.63%	-597.64%	-440.47%	-174.71%	-332.98%	-179.24%
EBITDA	-339.89	-338.83	-250.74	-163.47	-159.48	-99.03
EBITDA Margin	-	-	-	-207.99%	-	-135.97%
D&A For EBITDA	6.43	6.71	5.97	2.07	1.78	1.5
EBIT	-346.32	-345.54	-256.71	-165.53	-161.26	-100.53
EBIT Margin	-	-	-	-210.62%	-	-138.03%

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error